IGF2BP1 and colorectal carcinoma: MGAT5 was found to be a direct target of IGF2BP1 (Yang et al., 2021), and increased MGAT5 expression in CRC cells has been associated with enhanced N-glycosylation of key proteins and poor prognosis in CRC patients (de Freitas Junior and Morgado-Diaz, 2016).